Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data
Clinical Nephrology · 01.05.2022 · 97 (5) · 261-272
DOI: 10.5414/cn110516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology, erschienen am 01.05.2022. Verfasst von Ioannis Tomazos und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Atypical Hemolytic Uremic Syndrome. Die Arbeit wurde bisher 34-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Tomazos, I., Hatswell, A. J., Cataland, S., Chen, P., Freemantle, N., Lommele, Å., Deighton, K., Knowles, E., Sheerin, N. S., & Rondeau, E. (2022). Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clinical Nephrology, 97(5), 261-272. https://doi.org/10.5414/cn110516
Vancouver
Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele Å, et al. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clinical Nephrology. 2022;97(5):261-272. doi:10.5414/cn110516
BibTeX
@article{Tomazos2022,
author = {Tomazos, Ioannis and Hatswell, Anthony J and Cataland, Spero and Chen, Peter and Freemantle, Nick and Lommele, Åsa and Deighton, Kevin and Knowles, Emma and Sheerin, Neil S and Rondeau, Eric},
title = {Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data},
journal = {Clinical Nephrology},
year = {2022},
volume = {97},
number = {5},
pages = {261--272},
doi = {10.5414/cn110516}
}
EUVIMED